Claims

- 1. A pharmaceutical composition for the treatment of obesity, compulsive overeating, or to promote or facilitate weight loss comprising:
- (a) a nicotinic receptor partial agonist or a pharmaceutically acceptable salt 5 thereof;
 - (b) a CB-1 receptor antagonist or pharmaceutically acceptable salt thereof; and
 - (c) a pharmaceutically acceptable carrier;

10

15

20

25

30

35

wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating obesity, compulsive overeating or promoting or facilitating weight loss.

2. The pharmaceutical composition according to Claim 1, wherein said CB-1 receptor antagonist is selected from: 1-[9-(4-chloro-phenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-3-ethylamino-azetidine-3-carboxylic acid amide; 1-[9-(4-chloro-phenyl)-8-(2-chlorophenyl)-9Hamide; purin-6-yl]-3-ethylamino-azetidine-3-carboxylic acid 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide; 1-{1-[9-(4chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-yl}-ethanone; {3-[9-(4chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-3-(1α ,5 α ,6 α)-azabicyclo[3.1.0]hex-6-yl}-6-(1-benzylpyrrolidin-3-yloxy)-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9Hdimethylamine: purine; 9-(4-chlorophenyl)-6-(1-cyclohexylazetidin-3-yloxy)-8-(2,4-dichlorophenyl)-9H-purine; 6-tert-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine; 9-(4-chlorophenyl)-8-(2,4-1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9Hdichlorophenyl)-6-isopropoxy-9H-purine; purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2fluorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide; 1-[9-(4chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4isopropylaminopiperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-pyrrolidin-1-yl-piperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic acid amide; chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide; 8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8triazaspiro[4.5]decan-4-one; 9-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-methyl-4-oxa-1,9-diazaspiro[5.5]undecan-2-one; 8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9Hpurin-6-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-(4-fluorophenyl)-piperidin-4-ol; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-ol; 4-benzyl-1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-piperidin-4-ol; 4-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9Hpurin-6-yl]-piperazine-2-carboxylic acid methylamide; 9-(4-chlorophenyl)-8-(2,4-

dichlorophenyl)-6-(4-pyridin-2-yl-piperazin-1-yl)-9H-purine; and 9-(4-chlorophenyl)-8-(2,4-1-[9-(4-chlorophenyl)-8-(2dichlorophenyl)-6-(4-pyrimidin-2-yl-piperazin-1-yl)-9H-purine; fluorophenyl)-9H-purin-6-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; 1-[9-(4chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-isopropylamino-piperidine-4-carboxylic acid 4-amino-1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidine-4carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 4-amino-1-[9-(4-chloro-phenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-piperidine-4-carboxylic acid amide; and 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

5

10

piperidin-4-ol;

3. The pharmaceutical composition according to claim 1, wherein the CB-1 receptor antagonist is selected from: 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-15 methylpiperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2methyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-[(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-2methylpyrazolo[1,5-a][1,3,5]triazine; and 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-[4-(propane-2-sulfonyl)-piperazin-1-yl]-pyrazolo[1,5-a][1,3,5]triazine; 1-[7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-methylaminopiperidine-4-carboxylic 20 acid amide; 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-25 isopropylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3isopropylaminoazetidine-3-carboxylic acid amide; 3-amino-1-[7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide; 1-30 [7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3methylaminoazetidine-3-carboxylic acid amide; and 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-dimethylaminoazetidine-3-carboxylic acid amide; 1-{1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4phenylpiperidin-4-yl}-ethanone; 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-35 methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-azabicyclo[3.1.0]hex-6-ylamine; 1-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-(4-fluorophenyl)-4-benzyl-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-

2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2a][1,3,5]triazin-4-yl]-piperidin-4-ol; methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-5-methyl-2,5,7-triazaspiro[3.4]octan-8-one; 2-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5,7triazaspiro[3.4]octan-8-one; 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 2-[7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-6,6-dimethyl-2,5,7triazaspiro[3.4]octan-8-one; 4-(1-benzylpyrrolidin-3-yloxy)-7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-(1-cyclohexylazetidin-3-yloxy)-2-methylpyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-10 chlorophenyl)-4-isopropoxy-2-methylpyrazolo[1,5-a][1,3,5]triazine; and 4-tert-butoxy-7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine; butyl-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-amine; 7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-piperidin-1-yl-pyrazolo[1,5-a][1,3,5]triazine; [7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-[2-(4-15 fluorophenyl)-ethyl]-amine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-morpholin-4-ylpyrazolo[1,5-a][1,3,5]triazine; [7-(2-chlorophenyl)-8-(4-chlorophenyl)-2and methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-morpholin-4-yl-ethyl)-amine; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5carboxylic amide; 20 a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3amide; 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2carboxylic acid methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide; and 8-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-25 triazaspiro[4.5]decan-4-one; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

The pharmaceutical composition according to claim 1, wherein said CB-1 receptor antagonist is selected from: 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(4-methyl-3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(4piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine; 3-(4-chloro-phenyl)-2-(2pyrimidin-2-yl-piperazin-1-yl)-pyrazolo[1,5-a]pyrimidine; chlorophenyl)-7-[(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-pyrazolo[1,5a]pyrimidine; and 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-[4-(propane-2-sulfonyl)-piperazin-1-yl]-pyrazolo[1,5-a]pyrimidine; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4-isopropylaminopiperidine-4-carboxylic acid 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-3-amino-1-[3-(4-chlorophenyl)-2-(2ethylaminoazetidine-3-carboxylic acid amide;

30

chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-azetidine-3-carboxylic acid amide; 1-[3-(4chlorophenyl)-2-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3ethylaminoazetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide; 1-[3-(4chlorophenyl)-2-(2-chlorophenyl)-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5a]pyrimidin-7-yl]-3-methylaminoazetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid 1-{1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4amide; phenylpiperidin-4-yl}-ethanone; 3-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5a]pyrimidin-7-yl]-3-(1a,5a,6a)-azabicyclo[3.1.0]hex-6-ylamine; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4-(4-fluorophenyl)-piperidin-4-ol; 4-benzyl-1-[3-(4chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-piperidin-4-ol; 8-[3-(4chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-1-isopropyl-1,3,8triazaspiro[4.5]decan-4-one; 2-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5a]pyrimidin-7-yl]-2,5,7-triazaspiro[3.4]octan-8-one; 8-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 2-[3-(4chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-2,5,7triazaspiro[3.4]octan-8-one; 7-(1-benzylpyrrolidin-3-yloxy)-3-(4-chlorophenyl)-2-(2-3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(1chlorophenyl)-pyrazolo[1,5-a]pyrimidine; and cyclohexylazetidin-3-yloxy)-pyrazolo[1,5-a]pyrimidine; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4isopropylaminopiperidine-4-carboxylic acid amide; and 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

5

10

15

20

25

30

35

5. The pharmaceutical composition according to claim 1, wherein said CB-1 receptor antagonist is selected from: 5-(4-chloro-phenyl)-3-(5-cyclohexyl-1H-imidazol-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole; 5-(4-chloro-phenyl)-3-(2-cyclohexyl-3H-imidazol-4-yl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-3-[1-(1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-1-(2-chloro-phenyl)-3-[1-(2,2-dimethyl-tetrahydro-pyran-4-yl]-1H-imidazol-4-yl]-4-methyl-1H-pyrazole: 5-{2-(2,4-dichloro-phenyl)-4-methyl-5-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-2-methoxy-pyridine; and 1-(2-

chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of the compound or the salt.

5

10

15

20

25

30

35

- 6. The pharmaceutical composition according to claim 1, wherein said CB-1 receptor antagonist is selected from: 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1Hpyrazol-3-yl]-2-piperidin-1-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-1H-pyrrole-2-carbonyl)-piperazin-1-yl]-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methylcyclopropanecarbonyl)-piperazin-1-yl]-ethanone; N-(1-{2-[5-(4-chloro-phenyl)-1-(2-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxo-ethyl}-piperidin-4-yl)-2,2,2-trifluoro-acetamide; (4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-trifluoroacetylpiperazin-1-yl)-ethanone; 1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3yl]-2-pyrrolidin-1-yl-ethanone; 1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[1,4]oxazepan-4-yl-ethanone; and 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-oxa-8-aza-spiro[4.5]dec-8-yl)-ethanone; pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.
 - 7. The pharmaceutical composition according claim 1, wherein said CB-1 receptor antagonist is selected from: 2-(benzyl-isopropyl-amino)-1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-ethanol; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,5-dimethyl-piperidin-1-yl)-ethanol; 1-{2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-hydroxy-ethyl}-4-isopropylamino-piperidine-4-carboxylic acid amide; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,3-dimethyl-piperidin-1-yl)-ethanol; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanol; and 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanol; and a pharmaceutically acceptable salt thereof, or hydrate of the compound or the salt.

benzyl)-morpholine; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of the compound or the salt.

- 9. The pharmaceutical composition according claim 1, wherein said CB-1 receptor antagonist is selected from: 1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-piperidin-1-yl-ethanone and 1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-morpholin-4-yl-ethanone; and a pharmaceutically acceptable salt thereof, a or a solvate or hydrate of the compound, or the salt.
- 10. The pharmaceutically composition according to Claim 1, wherein said nicotinic receptor partial agonist is selected from:

```
9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-ethyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
9-bromo-3-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
```

3-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido [1,2-a][1,5] diazocin-8-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido [1,2-a][1,5] diazocin-8-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido [1,2-a][1,5] diazocin-8-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido [1,2-a][1,5] diazocin-8-benzyl-9-bromo-1,5-methano-pyrido [1,2-a][1,5] diazocin-8-benzyl-9-be

20 one:

25

30

5

3-benzyl-9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;

9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-ethynyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-(2-propenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;

one;

9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-

one;

one;

9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-

```
9-(4-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
        one;
                  9-(3-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
        one;
                  9-(3,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
 5
        one;
                  9-(2,4-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
        one;
                  9-(2,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
10
        one;
                  6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
                  5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
                  6-oxo-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
                  4,5-difluoro-10-aza-tricyclo[6,3,1,0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
15
                  4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  5-ethynyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
                  6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-
        triene:
                  10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
20
                  4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  4-methyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                  7-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
25
                  6-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                  6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                  6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-
        tetraene;
                 6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
30
                  5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                  14-methyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                  5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
                  6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
                  4-chloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
35
                  10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl cyanide;
                  1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;
```

```
10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-ol;
                   7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2,4(8),6,9-tetraene;
                   4,5-dichloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                   11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                   1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-ethanone;
 5
                   1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-propanone;
                   4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile:
                   5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-4-carbonitrile;
                   6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                   6-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
10
                   6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                   5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                   5,6-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                   5-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                   6-(trifluoromethyl)-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-1
15
        tetraene;
                  5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
                   7-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
                  6-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
20
                  6,7-dimethyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-
        pentaene;
                  7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                   5-methyl-7-oxa-6,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
25
                  7-methyl-5-oxa-6,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                  4,5-difluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  4-chloro-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  5-chloro-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  4-(1-ethynyl)-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
30
                   5-(1-ethynyl)-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  5,6-difluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
                  6-trifluoromethyl-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
                  6-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-6-ol;
35
                  6-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                   11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-ol;
```

4-nitro-11-aza-tricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-triene;

```
5-nitro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                5-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                6-hydroxy-5-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene; and
 5
       their pharmaceutically acceptable salts and their optical isomers.
                         The pharmaceutical composition according to Claim 10 wherein said nicotinic
       receptor partial agonist is selected from:
                9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
                9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
10
                9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
                9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
15
                9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
20
                9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-
       triene;
                4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
25
                4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                6-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
30
                6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
                10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl cyanide;
                1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;
                11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-ethanone;
35
                1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-propanone;
                4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
```

5-fluoro-11-azatricyclo[7.3.1.0^{2.7}]trideca-2(7),3,5-triene-4-carbonitrile;
6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2(10),3,5,8-tetraene;
6-methyl-5,7,14-triazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2(10),3,5,8-tetraene;
6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2(10),3,5,8-tetraene;
6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2(10),3,5,8-tetraene;
6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0^{2,10}.0^{4,8}]hexadeca-2(10),3,6,8-tetraene;
5,6-difluoro-11-aza-tricyclo[7.3.1.0^{2,7}]trideca-2,4,6-triene;
6-trifluoromethyl-11-aza-tricyclo[7.3.1.0^{2,7}]trideca-2,4,6-triene;
6-methoxy-11-aza-tricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-triene;

5

10

15

20

25

30

35

11-aza-tricyclo[7.3.1.0^{2.7}]trideca-2(7),3,5-trien-5-ol, and their pharmaceutically acceptable salts and their optical isomers thereof.

- 12. A method of treating obesity, overeating, and/or facilitating or promoting weight loss in a mammal comprising administering to said mammal respectively an anti-obesity attenuating effective amount of a pharmaceutical composition comprising
- (a) a nicotinic receptor partial agonist or a pharmaceutically acceptable salt thereof; and
- (b) a CB-1 receptor antagonist or a pharmaceutically acceptable salt thereof; wherein the active ingredients (a) and (b) are present in amounts that render the composition effective in the treatment of obesity, compulsive overeating or an overweight condition.
- 13. The method according to claim 12, wherein said CB-1 receptor antagonist is selected 1-[9-(4-chloro-phenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-3-ethylaminofrom: azetidine-3-carboxylic acid amide; 1-[9-(4-chloro-phenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-3ethylamino-azetidine-3-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9Hpurin-6-yl]-3-isopropylaminoazetidine-3-carboxylic acid amide; 1-{1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-yl}-ethanone; {3-[9-(4-chlorophenyl)-8-(2,4dichlorophenyl)-9H-purin-6-yl]-3- $(1\alpha,5\alpha,6\alpha)$ -azabicyclo[3.1.0]hex-6-yl}-dimethylamine; 6-(1benzylpyrrolidin-3-yloxy)-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine; 9-(4chlorophenyl)-6-(1-cyclohexylazetidin-3-yloxy)-8-(2,4-dichlorophenyl)-9H-purine; 6-tertbutoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine; 9-(4-chlorophenyl)-8-(2,4-1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9Hdichlorophenyl)-6-isopropoxy-9H-purine; purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2fluorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic amide; 1-[9-(4chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-propylaminopiperidine-4-carboxylic acid 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4amide; isopropylaminopiperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-

9H-purin-6-yl]-4-pyrrolidin-1-yl-piperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic acid amide; 1-[9-(4chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-isopropylaminopiperidine-4-carboxylic acid 8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8amide; triazaspiro[4.5]decan-4-one; 9-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-methyl-4-oxa-1,9-diazaspiro[5.5]undecan-2-one; 8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9Hpurin-6-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-(4-fluorophenyl)-piperidin-4-ol; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-phenylpiperidin-4-ol; 4-benzyl-1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-piperidin-4-ol; 4-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperazine-2-carboxylic acid methylamide; 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-pyridin-2-yl-piperazin-1-yl)-9H-purine; and 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4pyrimidin-2-yl-piperazin-1-yl)-9H-purine; 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2chlorophenyl)-9H-purin-6-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; 4-amino-1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidine-4-carboxylic acid amide; 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic acid 8-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-1-isopropyl-1,3,8amide; triazaspiro[4.5]decan-4-one; 4-amino-1-[9-(4-chloro-phenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]piperidine-4-carboxylic acid amide; and 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6yl]-4-ethylaminopiperidine-4-carboxylic acid amide; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

5

10

15

20

25

30

35

14. The method according to claim 12, wherein the CB-1 receptor antagonist is selected from 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-methylpiperazin-1-yl)pyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-pyrimidin-7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-2-ylpiperazin-1-yl)-pyrazolo[1,5-a][1,3,5]triazine; [(1S,4S)-5-methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-methylpyrazolo[1,5a][1,3,5]triazine; and 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-[4-(propane-2sulfonyl)-piperazin-1-yl]-pyrazolo[1,5-a][1,3,5]triazine; 1-[7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-methylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4isopropylaminopiperidine-4-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-

3-amino-1-[7-(2-chlorophenyl)-8-(4isopropylaminoazetidine-3-carboxylic acid amide; chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3methylaminoazetidine-3-carboxylic acid amide; and 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-5 2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-dimethylaminoazetidine-3-carboxylic acid amide; 1-{1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4phenylpiperidin-4-yl}-ethanone; 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-azabicyclo[3.1.0]hex-6-ylamine; 1-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-(4-fluorophenyl)-10 piperidin-4-ol; 4-benzyl-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5a][1,3,5]triazin-4-yl]-piperidin-4-ol; 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-5-methyl-2,5,7-triazaspiro[3.4]octan-8-one; 2-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-2,5,7triazaspiro[3.4]octan-8-one; 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-15 a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 2-[7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-6,6-dimethyl-2,5,7triazaspiro[3.4]octan-8-one; 4-(1-benzylpyrrolidin-3-yloxy)-7-(2-chlorophenyl)-8-(4chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-4-(1-cyclohexylazetidin-3-yloxy)-2-methylpyrazolo[1,5-a][1,3,5]triazine; 7-(2-chlorophenyl)-8-(4-20 chlorophenyl)-4-isopropoxy-2-methylpyrazolo[1,5-a][1,3,5]triazine; and 4-tert-butoxy-7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazine; butyl-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-amine; 7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-piperidin-1-yl-pyrazolo[1,5-a][1,3,5]triazine; [7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-[2-(4-25 fluorophenyl)-ethyl]-amine; 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-morpholin-4-ylpyrazolo[1,5-a][1,3,5]triazine; and [7-(2-chlorophenyl)-8-(4-chlorophenyl)-2methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-(2-morpholin-4-yl-ethyl)-amine; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-4-ethylaminopiperidine-4carboxylic amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-30 a][1,3,5]triazin-4-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-3-isopropylaminoazetidine-3amide; 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2carboxylic acid methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-azetidine-3-carboxylic acid amide; and 8-[7-(2chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl]-1-isopropyl-1,3,8-35 triazaspiro[4.5]decan-4-one; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

15. The method according to claim 12, wherein said CB-1 receptor antagonist is selected from: 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(4-methyl-piperazin-1-yl)-pyrazolo[1,5a]pyrimidine; 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(4-pyrimidin-2-yl-piperazin-1-yl)pyrazolo[1,5-a]pyrimidine; 3-(4-chloro-phenyl)-2-(2-chlorophenyl)-7-[(1S,4S)-5-5 methanesulfonyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-pyrazolo[1,5-a]pyrimidine; chlorophenyl)-2-(2-chlorophenyl)-7-[4-(propane-2-sulfonyl)-piperazin-1-yl]-pyrazolo[1,5a]pyrimidine; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4ethylaminopiperidine-4-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-4-isopropylaminopiperidine-4-carboxylic acid amide; 1-[3-(4-10 chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3carboxylic acid amide; 3-amino-1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5a]pyrimidin-7-yl]-azetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-isopropylaminoazetidine-15 3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-5,6-dimethylpyrazolo[1,5a]pyrimidin-7-yl]-3-ethylamino-azetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-methylaminoazetidine-3-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]-3ethylaminoazetidine-3-carboxylic acid amide; 1-{1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-20 pyrazolo[1,5-a]pyrimidin-7-yl]-4-phenylpiperidin-4-yl}-ethanone; 3-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-(1a,5a,6a)-azabicyclo[3.1.0]hex-6-ylamine; [3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4-(4-fluorophenyl)piperidin-4-ol; 4-benzyl-1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7yl]-piperidin-4-ol; 8-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-1-25 isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 2-[3-(4-chlorophenyl)-2-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-2,5,7-triazaspiro[3.4]octan-8-one; 8-[3-(4-chlorophenyl)-2-(2chlorophenyl)-6-methylpyrazolo[1,5-a]pyrimidin-7-yl]-1-isopropyl-1,3,8-triazaspiro[4.5]decan-4-one; 2-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-2,5,7triazaspiro[3.4]octan-8-one; 7-(1-benzylpyrrolidin-3-yloxy)-3-(4-chlorophenyl)-2-(2-30 chlorophenyl)-pyrazolo[1,5-a]pyrimidine; 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(1and cyclohexylazetidin-3-yloxy)-pyrazolo[1,5-a]pyrimidine; 1-[3-(4-chlorophenyl)-2-(2chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4-ethylaminopiperidine-4-carboxylic acid amide; 1-[3-(4-chlorophenyl)-2-(2-chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-4isopropylaminopiperidine-4-carboxylic acid amide; and 1-[3-(4-chlorophenyl)-2-(2-35 chlorophenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-3-ethylaminoazetidine-3-carboxylic acid amide; and a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

16. The method according to claim 12, wherein said CB-1 receptor antagonist is selected from: 5-(4-chloro-phenyl)-3-(5-cyclohexyl-1H-imidazol-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole; 5-(4-chloro-phenyl)-3-(2-cyclohexyl-3H-imidazol-4-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-3-[1-(1methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2-chlorophenyl)-4-methyl-3-[1-(1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; 5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; 5-(4chloro-phenyl)-1-(2-chloro-phenyl)-3-[1-(2,2-dimethyl-tetrahydro-pyran-4-yl)-1H-imidazol-4-yl]-4-methyl-1H-pyrazole: 5-{2-(2,4-dichloro-phenyl)-4-methyl-5-[1-(1-methyl-1-phenyl-ethyl)-1Himidazol-4-yl]-2H-pyrazol-3-yl}-2-methoxy-pyridine; and 1-(2-chloro-phenyl)-5-(4-chlorophenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole; and pharmaceutically acceptable salt thereof or a solvate or hydrate of the compound or the salt.

5

10

15

20

25

30

- 17. The method according to claim 12, wherein said CB-1 receptor antagonist is selected from: 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2piperidin-1-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3yl]-2-[4-(1-methyl-1H-pyrrole-2-carbonyl)-piperazin-1-yl]-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[4-(1-methyl-cyclopropanecarbonyl)-piperazin-1-yl]-ethanone; N-(1-{2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2oxo-ethyl}-piperidin-4-yl)-2,2,2-trifluoro-acetamide; 1-[5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2-fluorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-piperidin-1-yl-ethanone; 1-[5-(4-chloro-phenyl)-1-(2fluoro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-trifluoroacetyl-piperazin-1-yl)-ethanone; 1-[1-(2chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-pyrrolidin-1-yl-ethanone; 1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-[1,4]oxazepan-4-ylethanone; and 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-oxa-8-aza-spiro[4.5]dec-8-yl)-ethanone; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.
- 18. The method according claim 12, wherein said CB-1 receptor antagonist is 2-(benzyl-isopropyl-amino)-1-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4selected from: 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1Hmethyl-1H-pyrazol-3-yl]-ethanol; pyrazol-3-yl]-2-(3,5-dimethyl-piperidin-1-yl)-ethanol; 1-{2-[1-(2-chloro-phenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-hydroxy-ethyl}-4-isopropylamino-piperidine-4-carboxylic 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-2-(3,3acid amide: dimethyl-piperidin-1-yl)-ethanol; 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1Hpyrazol-3-yl]-2-piperidin-1-yl-ethanol; and 1-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-

1H-pyrazol-3-yl]-2-morpholin-4-yl-ethanol; a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

- 19. The method according to claim 12, wherein said CB-1 receptor antagonist is selected from: 2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-cyclohexyl-morpholine; 2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(propane-2-sulfonyl)-morpholine; 2-[5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(toluene-4-sulfonyl)-morpholine; 1-{2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-morpholin-4-yl}-2-methyl-propan-1-one; and 2-[1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazol-3-yl]-4-(4-trifluoromethyl-benzyl)-morpholine; a pharmaceutically acceptable salt thereof or a solvate or hydrate of the compound or the salt.
- 20. The method according claim 12, wherein said CB-1 receptor antagonist is selected from: 1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-piperidin-1-yl-ethanone and 1-[1-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-methyl-1H-imidazol-4-yl]-2-morpholin-4-yl-ethanone; a pharmaceutically acceptable salt thereof, a or a solvate or hydrate of the compound.
- 21. The method according to claim 12, wherein the nicotine partial agonist is selected from:

9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-ethyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-vinyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one; 9-bromo-3-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;

one;

one;

3-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-

3-benzyl-9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-

30 one;

5

10

15

20

25

35

9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-ethynyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-(2-propyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one; 9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;

```
9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
 5
                 9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 9-(4-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
10
                 9-(3-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 9-(3,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 9-(2,4-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
15
       one;
                 9-(2,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                 6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
                 5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
                 6-oxo-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
20
                 4,5-difluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                 5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
                 4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                 5-ethynyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
25
                 6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-
       triene;
                 10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                 4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                 4-methyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
30
                4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                7-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                6-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-
35
       tetraene;
                6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
```

5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2(11),3,5,7,9-pentaene;

```
14-methyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                  5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentádeca-2(10),3,6,8-tetraene;
                  6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
                  4-chloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
 5
                  10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl cyanide;
                  1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;
                  10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-ol;
                  7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2,4(8),6,9-tetraene;
                  4.5-dichloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
10
                  11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                  1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-ethanone;
                  1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-propanone;
                  4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                  5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-4-carbonitrile;
15
                  6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  5,6-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene:
20
                  5-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                  6-(trifluoromethyl)-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-
        tetraene;
                  5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
                  7-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
25
                  6-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;
                  6,7-dimethyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-
        pentaene;
                  7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
30
                  5-methyl-7-oxa-6,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                  6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                  7-methyl-5-oxa-6.14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                  4,5-difluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  4-chloro-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
35
                  5-chloro-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                  4-(1-ethynyl)-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
```

```
5-(1-ethynyl)-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                5,6-difluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
                6-trifluoromethyl-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
                6-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-6-ol;
 5
                6-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-ol;
                4-nitro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                5-nitro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                5-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
10
                6-hydroxy-5-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene
       and a pharmaceutically acceptable salt and an optical isomer thereof.
                22.
                          The method according to claim 12, wherein the nicotine partial agonist is
       selected from:
15
                9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
                9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
                9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
                9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
20
                9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
25
       one;
                9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
                9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-
       one;
                6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-
30
       triene;
                4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
                6-methyl-5,7,13-triazatetracyclo[9,3,1,0<sup>2,10</sup>,0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
                6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
35
                5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
                5-oxa-7.13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
```

```
6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
                 10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl cyanide;
                  1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;
                 11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-ethanone;
 5
                 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-propanone;
                 4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
                 5-fluoro-11-azatricyclo[7.3.1.0<sup>2.7</sup>]trideca-2(7),3,5-triene-4-carbonitrile;
                 6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                 6-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
10
                 6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                 6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
                 6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
                 5,6-difluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
                 6-trifluoromethyl-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6-triene;
15
                 6-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                 6-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene;
                 11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-ol;
                                                                                     and
                                                                                              the
                                                                                                       pharmaceutically
       acceptable salts and optical isomers thereof.
```

- 23. The method according to claim 12, wherein the nicotinic receptor partial agonist and the CB-1 receptor antagonist are administered substantially simultaneously.
- 24. A pharmaceutical composition according to claim 1 for treating a disorder or condition selected from the group consisting of disorders and conditions in which obesity or an overweight condition predominates, including Type 2 diabetes mellitus, hypertension, dyslipidemia and increased mortality in a mammal, the method comprising:
- (a) a nicotinic receptor partial agonist or a pharmaceutically acceptable salt thereof;
 - (b) a CB-1 receptor antagonist or a pharmaceutically acceptable salt thereof; and
 - (c) a pharmaceutically acceptable carrier;

20

25

30

35

wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating such disorder or condition.

- 25. A method of treating a disorder or condition according to claim 12 selected from the groups of disorders and conditions in which obesity or an overweight condition predominates in a mammal including Type 2 diabetes mellitus, hypertension, dyslipidemia and increased morality, the method comprising administering to said mammal:
- (a) a nicotinic receptor partial agonist ar a pharmaceutically acceptable salt thereof; and

(b) a CB-1 receptor antagonist or a pharmaceutically acceptable salt thereof; wherein the active agent "a" and "b" above are present in amounts that render the composition effective that render the composition effective in treating such disorder or condition.